Evidence map›Paper›PMID 38099276›Full record

ArticleNeurobiology of pain (Cambridge, Mass.)

Monoclonal antibodies against GFRα3 are efficacious against evoked hyperalgesic and allodynic responses in mouse join pain models but, one of these, REGN5069, was not effective against pain in a randomized, placebo-controlled clinical trial in patients with osteoarthritis pain.

Selin Somersan-Karakaya, Kenneth C Turner, Luz Cortes-Burgos, Jutta Miller, Michael LaCroix-Fralish, Veronika Logovinsky, Yamini Patel, Richard Torres, Samit Ganguly, Aurora Breazna and 16 more

Open access · goldAbstract read
In one paragraph

Article in Neurobiology of pain (Cambridge, Mass.). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Artemin sensitises mouse (Mus musculus) and naked mole-rat (Heterocephalus glaber) sensory neurons in vitro.Journal of comparative physiology. A, Neuroethology, sensory, neural, and behavioral physiology · 2025
    Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors at 2 institutions in 2 countries.

Selin Somersan-KarakayaRegeneron Pharmaceuticals, Inc., Tarrytown, NY, United States.
Kenneth C TurnerRegeneron Pharmaceuticals, Inc., Tarrytown, NY, United States.
Luz Cortes-BurgosRegeneron Pharmaceuticals, Inc., Tarrytown, NY, United States.
Jutta MillerRegeneron Pharmaceuticals, Inc., Tarrytown, NY, United States.
Michael LaCroix-FralishRegeneron Pharmaceuticals, Inc., Tarrytown, NY, United States.
Veronika LogovinskyRegeneron Pharmaceuticals, Inc., Tarrytown, NY, United States.
Yamini PatelRegeneron Pharmaceuticals, Inc., Tarrytown, NY, United States.
Richard TorresRegeneron Pharmaceuticals, Inc., Tarrytown, NY, United States.
Samit GangulyRegeneron Pharmaceuticals, Inc., Tarrytown, NY, United States.
Aurora BreaznaRegeneron Pharmaceuticals, Inc., Tarrytown, NY, United States.
Michelle DeVeauxRegeneron Pharmaceuticals, Inc., Tarrytown, NY, United States.
Rafia BhoreRegeneron Pharmaceuticals, Inc., Tarrytown, NY, United States.
Min GaoRegeneron Pharmaceuticals, Inc., Tarrytown, NY, United States.
Frank J DelfinoRegeneron Pharmaceuticals, Inc., Tarrytown, NY, United States.
Ashique RafiqueRegeneron Pharmaceuticals, Inc., Tarrytown, NY, United States.
Jeanette L FairhurstRegeneron Pharmaceuticals, Inc., Tarrytown, NY, United States.
Charleen HuntRegeneron Pharmaceuticals, Inc., Tarrytown, NY, United States.
Robert BabbRegeneron Pharmaceuticals, Inc., Tarrytown, NY, United States.
Ashok BaditheRegeneron Pharmaceuticals, Inc., Tarrytown, NY, United States.
William T PoueymirouRegeneron Pharmaceuticals, Inc., Tarrytown, NY, United States.
Ronald SurowitzHealth Awareness, Jupiter, FL, United States.
Sylvie RotteyGhent University Hospital, Ghent, Belgium.
Andrew J MurphyRegeneron Pharmaceuticals, Inc., Tarrytown, NY, United States.
Olivier HarariRegeneron Pharmaceuticals, Inc., Tarrytown, NY, United States.
Lynn E MacdonaldRegeneron Pharmaceuticals, Inc., Tarrytown, NY, United States.
Susan D CrollRegeneron Pharmaceuticals, Inc., Tarrytown, NY, United States.
Regeneron (United States) · USGhent University Hospital · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The artemin-GFRα3 signaling pathway has been implicated in various painful conditions including migraine, cold allodynia, hyperalgesia, inflammatory bone pain, and mouse knees contain GFRα3-immunoreactive nerve endings. We developed high affinity mouse (REGN1967) and human (REGN5069) GFRα3-blocking monoclonal antibodies and, following

Indexed as

GFRα3GFRα3-artemin signalingOsteoarthritis painREGN5069

Identifiers

PMID38099276
PMCPMC10719528
OpenAlexW4382044882

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.